Opinion
Video
Future Outlook for Atopic Dermatitis Treatments
Author(s):
Key Takeaways
- Novel oral systemic agents are being developed, targeting specific pathways in atopic dermatitis pathophysiology for improved efficacy and safety.
- Personalized medicine approaches and biomarkers are expected to enhance treatment outcomes by tailoring therapies to individual patient profiles.
Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.
EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis
EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis
EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients
EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis
EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice
EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis
EP: 7.Speed of Itch Relief in Atopic Dermatitis
EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis
EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis
EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data
EP: 11.Treatment Breaks and Rescue Treatments in Atopic Dermatitis
EP: 12.Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice
EP: 13.Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)
Now Viewing
EP: 14.Future Outlook for Atopic Dermatitis Treatments
Video content above is prompted by the following:
Please share final thoughts on the future of atopic dermatitis treatment with oral systemic agents.
Related Videos
Related Content
